Late last year GSK reported that their planned next generation drug Breo had failed to meet it's primary endpoint in asthma, copd and smokers cough. This was a phase 3, 16,500 people study. Phase 2 average success is 27% ( that's Invion), while phase 3 is 66% in respiratory. Breo was to replace blockbuster Advair whose sales are in decline due to generic competition. This has left a huge hole for GSK whose respiratory drugs account for a quarter of there sales.
Add to My Watchlist
What is My Watchlist?
